AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3883938
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy alone (n = 18)
Trial: 3883938
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus amitriptyline hydrochloride (n = 15)
Trial: 3883938
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment at one-year follow-up
Trial: 29273308
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) with carboplatin and paclitaxel (CT) followed by interval cytoreductive surgery and then 3 additional cycles of CT
Trial: 27447802
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg submucosal injection of prednisolone
Trial: 17916949
Drug: Adjuvant sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant sodium selenite 0.2 mg kg‐1 day‐1 for 30 days in addition to standard chemotherapy
Trial: 15613422
Drug: Flaxseed (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (40 g/d)
Trial: 7770605
Drug: Vitamin supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplementation (ten times the recommended daily dose of nine vitamins)
Trial: 17355546
Drug: Ergotamine 2
RxNorm normalized name: ergotamine 2 mg sublingual tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine 2 mg plus caffeine 200 mg
Trial: 6962709
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release oxprenolol (160-320 mg/day)
Trial: 6962709
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (oxprenolol and chlorthalidone, and hydrallazine)
Trial: 30477309
Drug: EDS‐FLU 93
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDS‐FLU 93 µg, 186 µg, or 372 µg
Trial: 10433447
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg allopurinol orally on admission and a further 300 mg for another 5 days
Trial: 1703602
Drug: Cromakalim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim (1 mg) single dose
Trial: 1703602
Drug: Cromakalim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim (1 mg) added to atenolol
Trial: 1703602
Drug: Cromakalim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim (1 mg)
Trial: 26261902
Drug: GAD antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibodies
Trial: 26261902
Drug: IA2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA2 antibodies
Trial: 31045465
Drug: Curcuminoids 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids 4 g/day
Trial: 22271159
Drug: Valsartan (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (320 mg)
Trial: 25853236
Drug: Nebivolol-Valsartan combination
RxNorm normalized name: nebivolol / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol-Valsartan combination (20/320 mg)
Trial: 16310713
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg oral morphine sulphate
Trial: 23419343
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg oral midazolam (active placebo)
Trial: 15293527
Drug: Manidipine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine (10-20 mg/day)
Trial: 2406298
Drug: Nicardipine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 90 mg/day
Trial: 7631894
Drug: Propranolol 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 240 mg/day
Trial: 30053856
Drug: Higher vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher vegetable intake (mean 324.6 ± 196.1 g/day)
Trial: 24509968
Drug: Adapalene-benzoyl peroxide
RxNorm normalized name: Adapalene-Benzoyl Peroxide Pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene-benzoyl peroxide topical gel
Trial: 23890405
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine
Trial: 22882692
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine (healthy controls)
Trial: 22882692
Drug: Adjuvanted vaccine
RxNorm normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccine (GMT)
Trial: 22882692
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine (GMT)
Trial: 22882692
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine (healthy controls, GMT)
Trial: 18180628
Drug: Hydrocodone/acetaminophen (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen (25 mg/2500 mg/d)
Trial: 18180628
Drug: Tramadol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (200 mg/d)
Trial: 12972172
Drug: LSG 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSG 1200 mg/day
Trial: 12972172
Drug: LSG 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSG 1500 mg/day
Trial: 3945915
Drug: Thermoradiotherapy (heating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoradiotherapy (heating tumor to 42-43.5 degrees C using electromagnetic waves at 915 MHz, total ionizing radiation dose of 40 Gy)
Trial: 3945915
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (radiation therapy only)
Trial: 9766765
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 mg t.i.d.) plus paroxetine (20 mg/day)
Trial: 8142123
Drug: Intraarterial chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial chemotherapy
Trial: 8142123
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone or radiotherapy combined with surgery and/or chemotherapy
Trial: 26253800
Drug: Buffered 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered 4% lidocaine with 1:100,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate
Trial: 11791098
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza virus vaccine (CAIV-T) administered by intranasal spray
Trial: 11791098
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza virus vaccine (CAIV-T)
Trial: 8736266
Drug: GHRH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (1 microgram/kg i.v.) combined with arginine (0.5 g/kg i.v.)
Trial: 361333
Drug: Oral oxprenolol
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxprenolol 80 mg
Trial: 26825017
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline at a dose of 1.5mlkg ‐1 h ‐1 for 12h before surgery
Trial: 18162832
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus (LGG) therapy for 4 weeks
Trial: 12681877
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of doxycycline orally twice a day for 7 days
Trial: 12681877
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of doxycycline orally twice a day for 3 days followed by an oral placebo twice daily for the last 4 days
Trial: 10389286
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg) every day for six months
Trial: 10389286
Drug: Premarin (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin (0.625 mg) every day plus Provera (5 mg) from day 1 to day 12 every month for six months
Trial: 8684694
Drug: Intracervical PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical PGE2 gel (0.5 mg) for cervical ripening and intravaginal PGE2 gel (2 mg) for induction of labor
Trial: 1880796
Drug: Tryptophan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (50 mg/kg/day)
Trial: 22646140
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of intravenous proton pump inhibitors (PPIs)
Trial: 22646140
Drug: High-dose intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intensive intravenous regimen of PPIs
Trial: 22646140
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of intravenous PPIs
Trial: 20219293
Drug: Chestnut's Bloomington
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chestnut's Bloomington Outpatient Treatment (CBOP) without ACC
Trial: 20219293
Drug: Chestnut's Bloomington
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chestnut's Bloomington Outpatient Treatment (CBOP) with ACC
Trial: 20219293
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) without ACC
Trial: 20219293
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) with ACC
Trial: 15901745
Drug: Progesterone (PG)
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone (PG) intravenous infusion
Trial: 9793768
Drug: Intraoperative mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin C (0.02% solution, applied for 3 minutes)
Trial: 7867870
Drug: Orlistat 80
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 80 mg, three times daily for 8 days
Trial: 356249
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren) 25 mg t.i.d. for 14 days
Trial: 356249
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg b.i.d. for 14 days
Trial: 9257670
Drug: Iloprost (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (8 hours/day i.v. infusion)
Trial: 9257670
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet medication (Control)
Trial: 3620398
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin protocol
Trial: 3620398
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin protocol
Trial: 20523971
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g glucose administration
Trial: 20523971
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose administration
Trial: 10773778
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) - 8 1-hour sessions of individual cognitive therapy for 6 weeks, followed by 6 2-hour sessions of social skills training (SST) in group weekly
Trial: 10773778
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) - after switching group 2 to CBT
Trial: 10773778
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy (ST) - 12 weeks (6 half-hour sessions)
Trial: 8873158
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose neuraxis irradiation (3,600 cGy/20 fractions)
Trial: 1736336
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine at bedtime for 2 weeks
Trial: 6093656
Drug: Aminophylline (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (9 mg/kg)
Trial: 20886791
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with acupoint sticking therapy (observation group)
Trial: 9661554
Drug: i.v. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketorolac 5 mg
Trial: 9661554
Drug: i.v. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketorolac 12.5 mg
Trial: 9661554
Drug: i.v. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketorolac 15 mg
Trial: 9661554
Drug: i.v. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketorolac 30 mg
Trial: 24401291
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g of bioactive collagen peptide (BCP) VERISOL® once daily for 8 weeks
Trial: 24401291
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g of bioactive collagen peptide (BCP) VERISOL® after 8 weeks
Trial: 18227295
Drug: Patient-specific heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific heparin concentration-based protocol
Trial: 18227295
Drug: Standard weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight-based heparin dose (400 U/kg)
Trial: 1962778
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy for stage II and IIIA nonsquamous cancer
Trial: 1962778
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for stage I disease
Trial: 1962778
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation therapy for stage II and IIIA squamous cell carcinoma
Trial: 6448429
Drug: naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500 mg initially, followed by 250 mg as needed, max 1250 mg daily)
Trial: 16111600
Drug: Intraoperative fluoroscopic
RxNorm normalized name: Fluoroacetic acid F-18
DrugBank: Fluoroacetic acid F-18 (DB15202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative fluoroscopic dose assessment (I-FL)
Trial: 16111600
Drug: Intraoperative fluoroscopic
RxNorm normalized name: Fluoroacetic acid F-18
DrugBank: Fluoroacetic acid F-18 (DB15202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative fluoroscopic dose assessment (I-FL) for Pd-103
Trial: 11825631
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin administration (SC)
Trial: 7128186
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide (200 mg)
Trial: 16998094
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (300 mg/d)
Trial: 26944539
Drug: Extended progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extended progesterone treatment combined with eCG
Trial: 23768612
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein (WP) 30 g
Trial: 23768612
Drug: Casein Protein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein Protein (CP) 30 g
Trial: 23768612
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) 33 g
Trial: 22439807
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone undecanoate (TU) four times/year for 36 months
Trial: 8920704
Drug: Schwarz standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz standard measles vaccine (SW-STD,10m)
Trial: 8920704
Drug: Schwarz high-titre
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz high-titre vaccine (SW-HT,5m)
Trial: 21992490
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) injection 0.015%
Trial: 17604592
Drug: Opioid monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid monotherapy (group OO)
Trial: 15555792
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group resuscitated according to the Baxter formula (4 ml/kg BW/% BSA burn)
Trial: 11173893
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG supplementation with standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.) for 14 days
Trial: 11173893
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., tinidazole 500 mg b.i.d.)
Trial: 9493716
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration (exact dosage and duration not specified)
Trial: 3501162
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (AP)
Trial: 30801621
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy (AC)
Trial: 17535146
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus an individually tailored exercise program administered twice daily from hospital admission to discharge
Trial: 8072075
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of 20 micrograms prostaglandin E1 with 10 mg procaine
Trial: 8072075
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection of 20 micrograms prostaglandin E1 with 20 mg procaine
Trial: 7817169
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose heparin
Trial: 25256813
Drug: One-third dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-third dose bacillus Calmette‐Guérin maintenance therapy every 6 months (3 weekly instillations)
Trial: 25256813
Drug: One-third dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-third dose bacillus Calmette‐Guérin maintenance therapy every 3 months (2 weekly instillations)
Trial: 25256813
Drug: One-third dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-third dose bacillus Calmette‐Guérin maintenance therapy
Trial: 23253774
Drug: Peri-interventional antibiotic
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-interventional antibiotic prophylaxis (1.2 g amoxicillin/clavulanic acid during stent insertion)
Trial: 23253774
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose antibiotic treatment (625 mg amoxicillin/clavulanic acid once daily until stent removal)
Trial: 16732095
Drug: Buprenorphine 0.05-0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.05-0.6 mg/70 kg
Trial: 15307696
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus 15 ml of milkvetch injection (MI) every 12 hrs for 14 days
Trial: 10835440
Drug: 1 mg/h
RxNorm normalized name: fentanyl 0.1 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/h nimodipine (low-dose)
Trial: 25185672
Drug: Alogliptin mono-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin mono-therapy
Trial: 22268920
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily for 60 days
Trial: 18492839
Drug: Prebiotic-supplemented hypoallergenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic-supplemented hypoallergenic formula (8 g/L scGOS/lcFOS)